Videnskab | Medicinsk Nyhed 28/09
Hormonsubstitution efter salpingo-ooforektomi hos BRCA1/2-mutationsbærere øger ikke risikoen for brystkræft
Ugeskr Læger 2014;176:V03130186
Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer
Prophylactic bilateral salpingo-oophorectomy (PBSO) reduces the risk of breast- and ovarian cancer in breast cancer gene (BRCA)1/2 mutation carriers. Women choose hormone replacement therapy (HT) to alleviate climacteric symptoms. Studies have shown a higher risk of breast cancer in healthy post-menopausal women getting HT. Further research among women with BRCA1/2 mutations is essential. No studies showed significantly that short-term use of HT alters the reduction in breast cancer risk associated with PBSO. Neither was there found any significant difference in type of HT chosen.